--- title: "Mabwell's ESG rating upgraded to A, with a composite score of 7.28, leading the pharmaceutical industry rating" type: "News" locale: "en" url: "https://longbridge.com/en/news/288560509.md" description: "On June 2, 2026, Mabwell's Wind ESG rating was upgraded from BB to A, with a comprehensive score of 7.28, ranking in the top 14.75% of the pharmaceutical industry. The company has made significant improvements in environmental, social, and governance dimensions, particularly excelling in wastewater and waste management as well as R&D investment, demonstrating strong ESG management capabilities" datetime: "2026-06-03T10:40:40.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/288560509.md) - [en](https://longbridge.com/en/news/288560509.md) - [zh-HK](https://longbridge.com/zh-HK/news/288560509.md) generator: "portal-rs" --- # Mabwell's ESG rating upgraded to A, with a composite score of 7.28, leading the pharmaceutical industry rating According to Tongbi Finance, on June 2, 2026, Mabwell (Shanghai) Biotechnology Co., Ltd. (stock abbreviation: Mabwell-U, code: 688062.SH) was upgraded from BB to A in the Wind ESG rating. The company's overall score is 7.28, higher than the pharmaceutical industry average of 5.86. It ranks 41st among 278 companies in the pharmaceutical industry, placing it in the top 14.75% of the industry. The scores for the environmental, social, and governance dimensions are 4.74, 6.52, and 6.52, respectively. Compared to the previous rating, the overall score increased from 5.80 to 7.28, an improvement of 1.48 points. Specifically, the score for management practices rose from 2.83 to 4.28, an increase of 1.45 points; the score for controversy events remained stable at 3.00. In terms of dimensions, the environmental dimension improved by 3.48 points, the social dimension by 2.06 points, and the governance dimension by 0.87 points. ## Rating Observation In the environmental dimension, the company has demonstrated a relatively complete management chain in wastewater and waste management, covering policy formulation, specific practices, and quantitative performance data. The company has established multiple environmental management systems, such as the "Hazardous Waste Management System" and the "Water Pollution Prevention and Control Management System," and has enhanced employees' awareness of environmental compliance through specialized training. The wastewater discharge volume is 29,686 tons, with both ammonia nitrogen and chemical oxygen demand at zero, and after treatment, it meets national and local environmental protection standards before being incorporated into the municipal sewage network. The company also conducts inactivation pretreatment for special wastewater containing biological activity and ensures compliant discharge through its self-built sewage treatment system. In terms of waste management, the company generated 116 tons of non-hazardous waste and 87 tons of hazardous waste throughout the year, which were classified and disposed of by property management or sanitation departments and qualified third parties. The disclosure of air emissions and raw material management is relatively brief, and there is still room for improvement in goal setting and system certification information. In the social dimension, the company has shown significant investment and management capabilities in research and innovation, while also demonstrating concern for employee rights in the employment sector. The company has established a management system covering the entire drug development process and set up a project management committee as the highest decision-making body for R&D investments. The proportion of R&D investment to operating income is as high as 147.46%, with the proportion of R&D employees at 28.23%, and the total number of effective patents reaching 88, indicating strong innovation capabilities. The company has also obtained certification for its intellectual property management system, establishing a fully digitalized mechanism for patent applications and copyright management. In the employment sector, the proportion of female employees is 51.09%, with an average salary of 358,700 yuan, and documents such as the "Recruitment Management System" and "Compensation Management System" ensure diversity and fair employment. Although the disclosure of customer satisfaction and development and training management system certification is not yet complete, overall, the company demonstrates strong capabilities in fulfilling social responsibilities. In the governance dimension, the company exhibits a strong structural checks and balances mechanism and audit supervision capabilities, but there is still room for improvement in diversification and the separation of executive roles. The proportion of independent directors on the board is 40%, with independent directors serving terms not exceeding 6 years and an attendance rate of 100%, indicating a certain level of independence and rotation mechanism The proportion of independent directors on the audit committee is 100%, with the chair being an independent non-executive director, and the convener having an accounting professional background, which strengthens the independence of audit supervision. However, the company's CEO also serves as the chairman, which may pose certain challenges to the independence of the board of directors. The proportion of female directors is 20%, and the proportion of female executives is 11.11%, indicating room for improvement in diversity. The low dissent rate on audit-related proposals suggests a high level of recognition from shareholders regarding the audit work, but the disclosure of information on the effectiveness assessment of the board of directors and the risk management committee still needs further improvement. Content generated by AI on June 3, 2026, please verify important information ### Related Stocks - [688062.CN](https://longbridge.com/en/quote/688062.CN.md) - [02493.HK](https://longbridge.com/en/quote/02493.HK.md) ## Related News & Research - [Mabwell passes Brazil ANVISA GMP inspection for denosumab biosimilars](https://longbridge.com/en/news/295337739.md) - [20:00 ETMabwell Announces Acceptance of Supplemental Biologics License Application by NMPA for MAIWEIJIAN (Denosumab)](https://longbridge.com/en/news/282910871.md) - [Qlife enters fully funded feasibility deal with global pharma company for Egoo Health biomarker application](https://longbridge.com/en/news/296995766.md) - [Tianjin Development FY26 H1 profit attributable to owners falls 5.58% to HK$ 325.22 million; revenue slips 3.53% to HK$ 1.66 billion](https://longbridge.com/en/news/297300410.md) - [Fosun turns page after property writedowns, shifts focus back to growth](https://longbridge.com/en/news/297240299.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**